Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MEDVidi vs MultiMedRx

MEDVidi
Graded #384

Higher grade

vs+0.3999999999999986
MultiMedRx
Graded #394

Lower grade

The verdict

MEDVidi takes it — 58/100 to 57.6/100, but only just.

MEDVidi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus… MultiMedRx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationEven
53
53
Clinical oversightMultiMedRx +2
77
79
Labs & monitoringMEDVidi +9
62
53
FulfillmentMultiMedRx +8
59
67
Contract termsMEDVidi +6
55
49
MEDVidi · left barMultiMedRx · right bar

The numbers

MetricMEDVidiMultiMedRx
WeighScore58/10057.6/100
GradeCC
Scorecard rank#384#394
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated
MultiMedRx

Graded #394 · C

Strengths

  • Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
  • Two physical addresses listed: Newport Beach, CA and Reno, NV
  • LegitScript seal present
  • Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
  • Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1

Where it loses points

  • No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
  • Monthly GLP-1 pricing isn't published — gated behind the consultation
  • $100 consultation fee adds friction; many peers bundle it into the medication price
  • Per-state availability not listed; only CA and NV offices disclosed
  • Whether compounded GLP-1 is offered isn't clear — verify during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard